Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP is expected to be releasing its earnings data before the market opens on Thursday, February 20th. Analysts expect Aurinia Pharmaceuticals to post earnings of $0.04 per share and revenue of $59.94 million for the quarter.
Aurinia Pharmaceuticals Stock Performance
Shares of NASDAQ AUPH traded up $0.10 during midday trading on Friday, reaching $7.93. The company had a trading volume of 1,298,613 shares, compared to its average volume of 1,264,245. Aurinia Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $10.67. The business's 50-day simple moving average is $8.33 and its 200 day simple moving average is $7.68. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The stock has a market cap of $1.13 billion, a P/E ratio of -52.83 and a beta of 1.22.
Analyst Ratings Changes
Separately, StockNews.com cut Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday.
Read Our Latest Report on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Company Profile
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Articles
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
